Sari K. Pesonen

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Cancer vaccines: an update on recent achievements and prospects for cancer therapy.

Cancer vaccines: an update on recent achievements and prospects for cancer therapy.

Journal: Clinical and experimental medicine

Published: August 26, 2024

Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.

Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.

Journal: Journal for immunotherapy of cancer

Published: February 18, 2024

PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.

PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.

Journal: International journal of biological macromolecules

Published: August 01, 2023

Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.

Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.

Journal: Frontiers in immunology

Published: November 30, 2021

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.

Journal: eLife

Published: June 11, 2021

Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy.

Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy.

Journal: Cancers

Published: June 03, 2021

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.

Journal: Molecular therapy oncolytics

Published: November 24, 2020

Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks.

Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks.

Journal: International journal of molecular sciences

Published: December 20, 2018

Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.

Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.

Journal: Journal of medical virology

Published: March 29, 2018

Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.

Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.

Journal: PloS one

Published: March 31, 2016

Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.

Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.

Journal: International journal of cancer

Published: February 22, 2016

Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.

Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.

Journal: Journal for immunotherapy of cancer

Published: August 25, 2015

Showing 1-12 of 30

Last Updated: 09/26/2026